Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 April 2007, Vol. 109, No. 7, pp. 2727-2735.
Prepublished online as a Blood First Edition Paper on November 16, 2006; DOI 10.1182/blood-2006-10-050807.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-10-050807v1
109/7/2727    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sethi, G.
Right arrow Articles by Aggarwal, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sethi, G.
Right arrow Articles by Aggarwal, B. B.
Related Collections
Right arrow Chemokines, Cytokines, and Interleukins
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CHEMOKINES, CYTOKINES, AND INTERLEUKINS

Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-{kappa}B–regulated gene products and TAK1-mediated NF-{kappa}B activation

Gautam Sethi1, Kwang Seok Ahn1, Manoj K. Pandey1, and Bharat B. Aggarwal1

1 Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX

Celastrol, a quinone methide triterpene derived from the medicinal plant Tripterygium wilfordii, has been used to treat chronic inflammatory and autoimmune diseases, but its mechanism is not well understood. Therefore, we investigated the effects of celastrol on cellular responses activated by TNF, a potent proinflammatory cytokine. Celastrol potentiated the apoptosis induced by TNF and chemotherapeutic agents and inhibited invasion, both regulated by NF-{kappa}B activation. We found that TNF induced the expression of gene products involved in antiapoptosis (IAP1, IAP2, Bcl-2, Bcl-XL, c-FLIP, and survivin), proliferation (cyclin D1 and COX-2), invasion (MMP-9), and angiogenesis (VEGF) and that celastrol treatment suppressed their expression. Because these gene products are regulated by NF-{kappa}B, we postulated that celastrol mediates its effects by modulating the NF-{kappa}B pathway. We found that celastrol suppressed both inducible and constitutive NF-{kappa}B activation. Celastrol was found to inhibit the TNF-induced activation of I{kappa}B{alpha} kinase, I{kappa}B{alpha} phosphorylation, I{kappa}B{alpha} degradation, p65 nuclear translocation and phosphorylation, and NF-{kappa}B–mediated reporter gene expression. Recent studies indicate that TNF-induced IKK activation requires activation of TAK1, and we indeed found that celastrol inhibited the TAK1-induced NF-{kappa}B activation. Overall, our results suggest that celastrol potentiates TNF-induced apoptosis and inhibits invasion through suppression of the NF-{kappa}B pathway.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
D. C. Hassane, M. L. Guzman, C. Corbett, X. Li, R. Abboud, F. Young, J. L. Liesveld, M. Carroll, and C. T. Jordan
Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data
Blood, June 15, 2008; 111(12): 5654 - 5662.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
G. Sethi, K. S. Ahn, B. Sung, and B. B. Aggarwal
Pinitol targets nuclear factor-{kappa}B activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis
Mol. Cancer Ther., June 1, 2008; 7(6): 1604 - 1614.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
A. Trott, J. D. West, L. Klaic, S. D. Westerheide, R. B. Silverman, R. I. Morimoto, and K. A. Morano
Activation of Heat Shock and Antioxidant Responses by the Natural Product Celastrol: Transcriptional Signatures of a Thiol-targeted Molecule
Mol. Biol. Cell, March 1, 2008; 19(3): 1104 - 1112.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Sors, F. Jean-Louis, E. Begue, L. Parmentier, L. Dubertret, M. Dreano, G. Courtois, H. Bachelez, and L. Michel
Inhibition of I{kappa}B Kinase Subunit 2 in Cutaneous T-Cell Lymphoma Down-Regulates Nuclear Factor-{kappa}B Constitutive Activation, Induces Cell Death, and Potentiates the Apoptotic Response to Antineoplastic Chemotherapeutic Agents
Clin. Cancer Res., February 1, 2008; 14(3): 901 - 911.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Abbas, A. Bhoumik, R. Dahl, S. Vasile, S. Krajewski, N. D.P. Cosford, and Z. A. Ronai
Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in Melanoma
Clin. Cancer Res., November 15, 2007; 13(22): 6769 - 6778.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020